Skip to content

Momentum leaders · current

US momentum leaders — July 2026

As of 2026-07-29

CRNX tops July's momentum table by a wide margin, at 128.624% over one month and 117.258% over three, with an acceleration reading of 133.595; behind it sit UTZ at 82.685% on the month and MAN, which carries a 90.488% three-month figure against 54.075% over one. The only themes that repeat are refining, where PARR (1m 47.154%) and PBF (1m 42.542%) both show up, and financial services, with GSHD at 43.109% and SAFT…

# Name 3-mo price move
1
CRNX
+119.9%

Momentum leg is dead: the story crystallized into Vertex's $85.00/share all-cash takeout (announced 2026-07-06, ~$10B). Shares gapped to ~$83.50…

2
UTZ
+77.5%

M&A event fully fired: Intersnack's $14.25/share all-cash take-private (announced 2026-07-21) gapped UTZ ~90% and pinned it at the offer. No…

3
HURN
+31.1%
4
CBZ
+69.1%

Activist-driven re-rate on a cheap professional-services roll-up: Reference Equity's July 7 letter to halt buybacks and resume M&A drove a +9.3%…

5
MAN
+84.9%

Cyclical staffing earnings inflection: Q2 beat (adj EPS $0.99 vs $0.95; rev $4.86B vs $4.72B) plus an above-street Q3 guide ($0.96–1.06 vs $0.88)…

6
PAY
+29.8%

Beaten-down bill-pay compounder: Q1 2026 revenue +30.2% YoY yet shares carved a $20.11 June 52-week low on margin-mix fear. Now ~40% off that low…

7
MANH
+47.4%
8
RNG
+47.9%

Beaten-down UCaaS name popped ~24% on a 2026-07-23 Q2 beat-and-raise plus an OpenAI-adoption headline. But sell-side stayed Neutral (PTs $40–43),…

9
BLKB
+15.4%
10
CTSH
+4.1%
11
GSHD
+43.8%

Sell-side is re-rating GSHD ahead of the tape: five price-target raises in eight days (Piper $52→$72, Cantor $76, UBS $70, JPM $60, RBC $55)…

12
PARR
+32.7%

Independent refiner ripping on a record 3-2-1 crack spread (~$70/bbl, 2026-07-16) and the Iran/Strait-of-Hormuz premium; sell-side chasing with PT…

13
LAD
+53.6%
14
ATRC
+43.5%
15
ACN
−0.7%
16
TNET
+72.1%

Insurance-cost-ratio recovery is the whole story: Q1 2026 ICR of 84% vs ~90% guide drove a +10% pop, and shares ran ~+75% off the $33.60 low to…

17
COTY
+12.9%

Distressed, highly-levered beauty turnaround (net debt ~$3.17B, ~3.3-3.4x) bouncing +23% off its ~$1.82 all-time low on the ~$400M Gucci license…

18
EXLS
+17.7%
19
AVTR
+80.1%
20
GWRE
+22.1%

Vertical-SaaS insurance compounder de-rated ~52% from its $272 high; the 2026-06-04 Q3 beat-and-raise (rev +27%, ARR $1.147B) was sold and price…

21
WEX
+24.8%

Hated fuel-card/fintech inflecting: the 2026-07-22 Q2 beat (Adj EPS $5.35 vs $5.05) and FY26 guide raise to $19.68-$20.08 discredit the…

22
PCTY
+43.5%
23
NIQ
+8.3%

Newly-public consumer-measurement franchise (ex-NielsenIQ + GfK, Advent-backed) rebranding as an AI retail-media platform via a stream of…

24
WDAY
+40.5%
25
ENOV
+29.2%

Post-Colfax orthopedic pure-play turnaround: LimaCorporate integration plus FCF-conversion recovery (43% in 2024 toward a 70–80% target) is the…

26
SAFT
+35.3%

All-cash $105 Mapfre buyout signed 2026-07-23; the +37.58% announcement gap already fired, so SAFT is now a ~4.6% merger-arb spread into a Q1 2027…

27
LZ
+28.0%

AI-reset narrative — a busted online legal-forms IPO repositioning as an AI-enabled SMB subscription platform (Anthropic partner, AI "digital…

28
THC
+44.9%
29
HUBS
+11.6%
30
KARO
+34.0%

Founder-led fleet-telematics compounder: Q1 FY2027 (2026-07-15) delivered a record 142,472 net Cartrack adds (+70% YoY) and +22% group revenue,…

31
PBF
+55.2%

Pure merchant refiner, the highest-beta play on crack spreads. Narrative is a refining-margin shock — ~10% of global capacity reported offline…

32
BVS
+34.2%

De-levering small-cap orthobiologics turnaround, now maturing: the July-2025 refi killed the 2026 debt wall, margins inflected above 20%, and the…

33
WIX
−19.5%
34
EPAM
−5.0%
35
TASK
+2.5%
36
PAYC
+37.6%
37
CRAI
+25.2%
38
PYPL
+19.9%

Live takeover: Stripe/Advent's $60.50 bid (>$53B) sent PYPL +17.2% to $56.56; board called it inadequate (Reuters 2026-07-17), leaving a ~7% gross…

39
WPP
+26.4%
40
BILL
+27.1%

Beaten-down B2B-fintech turnaround re-rating on self-help: Q3 delivered the first GAAP-profitable quarter, a $1.0B buyback, and a 30% headcount…

41
BCO
+13.1%
42
CLW
+44.4%
43
DXC
+2.0%
44
ATAI
+65.7%

Rumor confirmed and cashed: Eli Lilly is acquiring AtaiBeckley (announced 2026-07-16) for $6.75/share cash plus up to $2.50 CVR tied to…

45
G
+9.3%
46
TEAM
+51.7%
47
LPG
+24.7%

Hormuz truce collapsed 2026-07-08 — Iran re-struck shipping and re-closed the Strait, re-firing VLGC rates to fresh 2026 highs (BLPG3 $220/ton,…

48
EQNR
+6.7%

European winter gas-security theme re-accelerating; Equinor, the swing Norwegian pipeline supplier, held ~$40 through a Q2 double-miss on a…

49
ETON
+99.7%

Q1 beat-and-raise (adj EPS $0.14 vs $0.09, FY26 guide lifted above $120M, 2026-05-14) confirmed the specialty-pharma rollup, but the story stopped…

50
ADBE
+9.0%

"3-mo price move" is the stock's market price change, not an orbyd return.

How this board is built

Every name in the US equity universe is scored on cross-sectional 3-month price momentum by a frontier model and ranked highest-first. The board reflects price moves already made, not a forecast. Each covered name links to its dated research dossier — thesis, invalidation trigger, archetype and catalyst.

Questions

What are the hottest US stocks right now?
As of 2026-07-29, the US names with the strongest 3-month price momentum on orbyd are CRNX, UTZ, HURN, CBZ. This is a momentum ranking of price moves already made — research, not advice.
How is this momentum ranking built?
A frontier model scores every name in the US equity universe on cross-sectional 3-month price momentum, then ranks them highest-first. Each covered name links to its dated research dossier. Methodology is open.
Is a high ranking a recommendation?
No. The board reflects price moves that have already happened, not a forecast or a recommendation. It is educational research, not investment advice.

As of 2026-07-29 · research, not advice.